(PC) Price v. Iqbal

CourtDistrict Court, E.D. California
DecidedJune 30, 2022
Docket2:20-cv-01439
StatusUnknown

This text of (PC) Price v. Iqbal ((PC) Price v. Iqbal) is published on Counsel Stack Legal Research, covering District Court, E.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
(PC) Price v. Iqbal, (E.D. Cal. 2022).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 FOR THE EASTERN DISTRICT OF CALIFORNIA 10 11 IMMANUEL C. PRICE, No. 2:20-cv-01439-TLN-KJN P 12 Plaintiff, 13 v. ORDER 14 Z. IQBAL, et. al., 15 Defendants. 16 17 I. Introduction 18 Plaintiff Immanuel C. Price, a state prisoner proceeding pro se, filed a civil rights action 19 seeking relief under 28 U.S.C. § 1983. He alleges that, while he was housed at High Desert State 20 Prison, defendants Iqbal, Rueter, and Gates ignored his serious medical needs by refusing to 21 continue his prescription of gabapentin as neuropathy treatment.1 (ECF No. 1.) He alleges that 22 defendants’ actions constituted deliberate indifference under the Eighth Amendment, negligence, 23 and violated Government Code section 845.6. (Id. at 3-12.) 24 Defendants filed a motion to dismiss on the grounds that plaintiff failed to state a medical 25 deliberate indifference claim and that defendants are entitled to qualified immunity. (ECF Nos. 26 1 This Court screened his complaint and determined that plaintiff’s claim against defendant 27 Kehinde was not properly joined with plaintiff’s Eighth Amendment claim against the remaining defendants. (ECF No. 10 at 2.) Consequently, this Court dismissed defendant Kehinde from the 28 action without prejudice. (ECF No. 24.) 1 39, 46, & 51.) Because plaintiff fails to state a cognizable federal claim, defendants contend that 2 this Court should decline to exercise supplemental jurisdiction over his state law claims. (ECF 3 Nos. 39, 46, & 51.) Plaintiff opposed this motion and filed a request for judicial notice. (ECF 4 Nos. 41, 45, 49, & 50.) For the reasons that follow, defendants’ motion to dismiss is granted, 5 with leave to amend, and plaintiff’s requests for judicial notice are denied. 6 II. The Complaint 7 Plaintiff was diagnosed with Non-Hodgkin’s Lymphoma in October 2012 while 8 incarcerated and he underwent surgery and chemotherapy. (ECF No. 1 at 3 & Ex. A.) After 9 chemotherapy, plaintiff experienced tingling, burning, and numbness in his hands and feet and 10 was diagnosed with neuropathy. (Id.) Doctors treated his condition with different topical creams 11 and medications with varying degrees of success and side effects. (Id.) Those drugs included 12 nortriptyline, amitriptyline, duloxetine, carbamazepine, Cymbalta, venlafaxine, Effexor, Elavil, 13 ibuprofen, naproxen, and acetaminophen, although some of those medications were prescribed for 14 anxiety and depression. (ECF No. 1 at 3, 18, 22.) 15 In August 2017, a non-defendant doctor prescribed gabapentin, initially at 300 mg twice 16 daily and increased the dosage to 800 mg twice daily. (Id. at 4, 18.) Plaintiff alleges that 17 gabapentin offered him the most relief without any side effects. (Id.) 18 Plaintiff was later transferred to High Desert State Prison. (Id.) In December 2019, 19 defendant Dr. Iqbal began tapering off plaintiff’s gabapentin dosage with a goal of ending his 20 prescription by January 19, 2020. (Id. at 4-5, 7, 20.) Plaintiff alleged that he did not talk to Dr. 21 Iqbal about the change until January 14, 2020.2 (Id. at 4-5, 26.) In its place, Dr. Iqbal offered 22 plaintiff other medications, but plaintiff told Dr. Iqbal that those medications had been ineffective 23 in the past. (Id. at 27.) Dr. Iqbal refused to extend his prescription for gabapentin. (Id. at 5, 27 24 (“Despite extensive counseling, [patient] refused to accept any alternatives to gabapentin. He 25 appears to be functioning well so he does not have medical necessity for treatment with 26 2 In a health care grievance attached to the complaint, plaintiff states that he went to clinic on 27 December 26, 2019 to talk to a doctor about his gabapentin prescription. The medical staff told him he needed to be weighed before seeing the doctor. Plaintiff refused and left the clinic. (ECF 28 No. 1 at 34.) 1 nonformulary medications.”)) In medical progress notes dated February 7, 2020, it was noted that 2 “[p]atient is here for alternatives to gabapentin. He has tried Cymbalta, carbamazepine, Effexor, 3 Elavil, nortriptyline, ibuprofen, naproxen, and acetaminophen…He is willing to try Lyrica.” (Id. 4 at 22.) The notes also stated 5 [c]ounseled patient that gabapentin only has two indications and that it is being restricted statewide, reviewing the memorandum dated 6 April 18, 2019 with him. Counseled patient that Lyrica may also not fit his indication but will review with CME. He has never had 7 physical therapy and is willing to try it so he does not need medication every day Requested [physical therapy]. Follow up after 8 [physical therapy] consult. 9 (Id. at 22.) 10 In response to his prescription change, plaintiff filed a medical grievance. (Id. at 5, 32- 11 35.) Defendant Dr. Rueter, High Desert State Prison Chief Medical Executive, affirmed Dr. 12 Iqbal’s decision. (Id. at 5-6, 29-30.) In a letter dated February 27, 2020, Dr. Rueter explained 13 [p]rescriptions/orders shall be limited to the medications listed in the California Correctional Health Care Services Formulary, unless 14 otherwise provided by the non-formulary process in accordance with the Health Care Department Operations Manual, Section 3.5.4, 15 CCHCS Drug Formulary. The primary care provider did not document a current condition that meets the criteria for non- 16 formulary use of gabapentin. 17 Your medical condition will continue to be monitored with care provided as determined medically or clinically indicated by the 18 primary care provider. 19 (Id. at 30.) 20 Defendant Dr. Gates, Chief Health Care Correspondence and Appeals Branch, affirmed 21 Drs. Rueter and Iqbal’s decisions. (Id. at 5-6, 29-31; see also id. at 37.) 22 Attached to the complaint is California Correctional Health Care Services Memorandum 23 dated April 18, 2019 regarding gabapentin. (Id. at Ex. D at 39.) The memorandum states 24 On February 12, 2019, the Systemwide Pharmacy and Therapeutics Committee reviewed gabapentin, its utilization, and recent patient- 25 safety concerns with the drug. Given its high utilization at some institutions in the California Correctional Health Care Services, the 26 Committee has decided to restate gabapentin’s place in therapy. 27 Gabapentin is a non-formulary medication that is FDA approved for the following two indications: (1) partial seizures and (2) 28 1 postherpetic neuralgia. There is minimal and weak evidence to support gabapentin use in the treatment of other types of neuropathic 2 pain, including diabetic neuropathy. 3 Recent articles have questioned the safety of gabapentin as studies have found: 4 • 40 to 65% of people prescribed gabapentin misuse the 5 medication. 6 • 15 to 22% of people abusing opioids also abuse gabapentin. 7 • Autopsies and toxicology screenings discovered 22% of people who died from a drug overdose had gabapentin 8 present in their systems. 9 • Concomitant gabapentin and opioid exposure was associated with a 49% higher risk of dying from an opioid overdose. 10 As such, five states, with more pending, have reclassified gabapentin 11 as a controlled substance because of its propensity for abuse. 12 The Committee urges health care providers to limit prescribing gabapentin to its FDA-approved indications as clinically appropriate. 13 You are directed to train institutional clinical state to implement. 14 15 (Id. at 39.) 16 Between the date of this memorandum and December 2019, no other doctor adjusted 17 plaintiff’s gabapentin prescription. (Id. at 7.) He alleges that Dr. Iqbal, therefore, “was not 18 obligated to discontinue [his] gabapentin prescription, but desired to do so to please his 19 supervisor(s), and committed classic willful blindness….” (Id. at 7-8.) Since being taken off 20 gabapentin, plaintiff consulted with two non-defendant doctors, one of which indicated that 21 gabapentin is the best neuropathy medication. (Id. at 8, 41.) 22 III.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Haines v. Kerner
404 U.S. 519 (Supreme Court, 1972)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Rodriguez v. Popular Democratic Party
457 U.S. 1 (Supreme Court, 1982)
Hishon v. King & Spalding
467 U.S. 69 (Supreme Court, 1984)
Wilson v. Seiter
501 U.S. 294 (Supreme Court, 1991)
Helling v. McKinney
509 U.S. 25 (Supreme Court, 1993)
Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Bartlett v. Strickland
556 U.S. 1 (Supreme Court, 2009)
Pearson v. Callahan
555 U.S. 223 (Supreme Court, 2009)
Barbara P. Hutchinson v. United States of America
838 F.2d 390 (Ninth Circuit, 1988)
Toguchi v. Soon Hwang Chung
391 F.3d 1051 (Ninth Circuit, 2004)
Farmer v. Brennan
511 U.S. 825 (Supreme Court, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
(PC) Price v. Iqbal, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pc-price-v-iqbal-caed-2022.